

## ***Corrigendum***

# **Corrigendum to “Effectiveness of Delayed-release Dimethyl Fumarate on Clinical and Patient-reported Outcomes in Patients With Relapsing Multiple Sclerosis Switching From Glatiramer Acetate: RESPOND, a Prospective Observational Study” [Clinical Therapeutics 40 (12) (2018) 2077–2087]**



Kiren Kresa-Reahl, MD<sup>1</sup>; Pavle Repovic, MD<sup>2</sup>; Derrick Robertson, MD<sup>3</sup>; Macaulay Okwuokenye, DrPH<sup>4</sup>; Leslie Meltzer, PhD<sup>4</sup>; and Jason P. Mendoza, PhD<sup>4</sup>

<sup>1</sup>Providence Multiple Sclerosis Center, Portland, OR, USA; <sup>2</sup>Multiple Sclerosis Center, Swedish Neuroscience Institute, Seattle, WA, USA; <sup>3</sup>USF Multiple Sclerosis Center, Tampa, FL, USA; and <sup>4</sup>Biogen, Cambridge, MA, USA

---

The authors regret that on page 8, table IV, the number of hepatic and colon cancer stage IV events was reported incorrectly as 2 (<1). In fact, 2 events were reported in the same patient and the n number should therefore be n=1 (<1%). The footnote to the table has been changed to reflect this i.e., ‘reported by physician (two events, same patient).’ The authors would like to apologise for any inconvenience caused.

Address correspondence to. Mr. Mendoza E-mail: [jason.mendoza@biogen.com](mailto:jason.mendoza@biogen.com)

<https://doi.org/10.1016/j.clinthera.2018.10.011>

---

<https://doi.org/10.1016/j.clinthera.2019.06.001>

0149-2918/\$ - see front matter

© 2019 Published by Elsevier Inc.